A treatment stratification test for early-stage lung cancer

Confident treatment decisions in NSCLC

40,000 patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.1

30-50% of early-stage patients will not survive despite complete surgical resection.2

We need a better way to understand which patients may benefit from chemotherapy.

DetermaRx is a treatment stratification test to identify patients with Stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.2


Identify your patients who may benefit from chemotherapy


Order DetermaRx for your patient with stage I or IIA non-squamous NSCLC undergoing resection.


We analyze the molecular signature of your patient’s tumor tissue to stratify your patient’s risk.


Make informed treatment decisions for your patient following surgery.

Clinical Evidence

  • DetermaRx is a 14-gene molecular stratification test that has been validated in two independent cohorts with close to 1400 patients.3
  • DetermaRx outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIA non-squamous NSCLC.3
  • Patients identified by DetermaRx as high-risk* and who were treated with adjuvant platinum chemotherapy had 91.7% 5-year disease-free survival compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy.2
  • In a study of physician practices, DetermaRx results led to a change in treatment recommendation for 30% of patients.4

*Test identified intermediate- and high-risk patients were grouped together in this analysis and designated as molecular high-risk.


Billing & Resources

At Oncocyte, we are committed to providing accessible, affordable testing for all.

Insurance & eligibility

We accept all insurance on an out-of-network basis. We will contact you if your estimated out-of-pocket cost exceeds $100.

Financial Assistance

We realize that each patient’s situation is unique and offer a Patient Assistance Program to assist with the costs of our test.
View Form

We’re Here to Help

Our billing specialists can verify insurance eligibility and answer any questions you have. Please contact us at 1-844-662-6298.

Contact Us

Interested in offering DetermaRx to your patients? Please contact us to receive information about our early access program.


1. Meza, et al. (2015) Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One 10:e0121323.
2. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
3. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
4. Dormady, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59.
5. Kratz, et al. (2019) Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. Journal of Thoracic Oncology 14:1223.
6. Kratz, et al. (2012) A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 308:1629.
7. Kratz, et al. (2013) Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagnostic Molecular Pathology. 22:65.
8. Woodard, et al. (2014) Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small cell lung cancer. Clinical Lung Cancer 15:426.